| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Toronto-based, Organigram Holdings Inc. (NASDAQ:OGI) announced promising preliminary results from a landmark clinical study on their new nanoemulsion technology. This innovation, branded FAST (Fast Acting Soluble Technology) aims to innovate the company’s edibles products. The study, part of the Product Development Collaboration (PDC), highlights the potential benefits of this nanoemulsion technology, which has recently been explored in the cannabis industry.
According to the company, the clinical study – completed in January 2024 – has shown significant advances. Organigram has been a long time explorer of these types of developments. In this case, the technology demonstrated a faster onset of effects, up to 50% quicker compared to traditional ingestible products. Additionally, the study found improved bioavailability, with up to double the cannabinoid delivery at peak compared to the control group. Early indicators also suggest a more predictable duration of effects, promising future product development. Interestingly, results are coming from PDC, which is a joint collaboration between British American Tobacco (BAT) and Organigram, established to focus on developing new cannabis products.
Organigram’s SVP of Innovation and R&D, Borna Zlamalik, emphasized that the patent-pending nanoemulsion technology, FAST, promises to unlock the power of ingested cannabinoids and allow consumers to control their dosage experience more accurately.
“These technological advances underscore Organigram's commitment to consumers and to developing science-driven innovations", Zlamelik stated.
Organigram plans to use the data to support technology claims, adhering to Health Canada regulations. Zlamalik added that as a responsible licensed producer, their aim is to thoroughly educate consumers about the effects of this technology, empowering them to enjoy a controlled and predictable ingestible experience.
Read Also: These Companies Teamed Up To Develop CBD-Nanoemulsion Sports Performance/Recovery Drinks
The study, one of the largest targeting adult-use recreational cannabis products, was a 19-day, eight-arm in-clinic evaluation of cannabinoid absorption across three key product formats. A leading third-party clinical research organization conducted the study. Organigram plans to commercialize FAST in fall 2024, starting with gummies. In fact, manufacturing trials for these gummies are underway at Organigram's Winnipeg facility.
Beena Goldenberg, CEO of Organigram, highlighted the company’s focus on consumer-centric innovation, stating that their commitment to the development of advanced technologies underscores the company’s dedication to success in the edibles space both domestically and abroad.
Cover: Photo by Kindel Media via Pexels
Posted In: OGI
